Immuneering Corp (NASDAQ: IMRX) is -66.94% lower on its value in year-to-date trading and has touched a low of $1.00 and a high of $8.89 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IMRX stock was last observed hovering at around $2.32 in the last trading session, with the day’s gains setting it 0.11%.
Currently trading at $2.43, the stock is 12.80% and 56.38% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.77 million and changing 4.74% at the moment leaves the stock -21.97% off its SMA200. IMRX registered -65.68% loss for a year compared to 6-month loss of 1.25%. The firm has a 50-day simple moving average (SMA 50) of $1.5787 and a 200-day simple moving average (SMA200) of $3.08785.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 100.83% gain in the last 1 month and extending the period to 3 months gives it a 115.04%, and is -17.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.09% over the week and 21.78% over the month.
Immuneering Corp (IMRX) has around 68 employees, a market worth around $72.05M and $0.00M in sales. Distance from 52-week low is 143.00% and -72.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-79.75%).
The EPS is expected to shrink by -0.30% this year
74.0 institutions hold shares in Immuneering Corp (IMRX), with institutional investors hold 45.90% of the company’s shares. The shares outstanding are 29.27M, and float is at 21.00M with Short Float at 14.39%. Institutions hold 32.51% of the Float.
The top institutional shareholder in the company is CITADEL ADVISORS LLC with over 1.88 million shares valued at $2.41 million. The investor’s holdings represent 6.4083 of the IMRX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.07 million shares valued at $1.37 million to account for 3.6442 of the shares outstanding. The other top investors are MILLENNIUM MANAGEMENT LLC which holds 0.95 million shares representing 3.2455 and valued at over $1.22 million, while PRICE T ROWE ASSOCIATES INC /MD/ holds 2.926 of the shares totaling 0.86 million with a market value of $1.1 million.
Immuneering Corp (IMRX) Insider Activity
The most recent transaction is an insider sale by Cormorant Asset Management, LP, the company’s 10% Owner. SEC filings show that Cormorant Asset Management, LP sold 400,000 shares of the company’s common stock on Apr 01 ’24 at a price of $2.90 per share for a total of $1.16 million. Following the sale, the insider now owns 2.9 million shares.
Immuneering Corp disclosed in a document filed with the SEC on Mar 22 ’24 that Schall Thomas J. (Director) bought a total of 2,900 shares of the company’s common stock. The trade occurred on Mar 22 ’24 and was made at $2.55 per share for $7385.0. Following the transaction, the insider now directly holds 2900.0 shares of the IMRX stock.
Still, SEC filings show that on Mar 22 ’24, Feinberg Peter (Director) acquired 25,000 shares at an average price of $2.55 for $63713.0. The insider now directly holds 111,766 shares of Immuneering Corp (IMRX).
